Breast Cancer in Transgenders: Narrative Review
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(01): 003-008
DOI: DOI: 10.1055/s-0041-1740140
Abstract
The molecular pathogenesis of breast cancer (BC), the second most common cancer, varies significantly between sexes, with minimal data in the transgender population. The overall prevalence of BC in transgenders is estimated to be 0.02%. Besides experiencing social disparities, transgenders have to face a lot of discrimination in the healthcare system. Adversities faced, along with the urge to identify with physical attributes to the gender felt by them, forces transgenders to use non-prescribed hormones. Gender affirming hormone therapy (GAHT) is a key feature of transition-related care, rehabbing mental health, and the quality of life of transgenders, but at the expense of their health. Studies have reported that GAHT is associated with severe health conditions such as cancer in transgenders. Estrogens and testosterone are associated with a moderate risk of developing BC. The types of BC diagnosed in transgenders after cross-sex hormone therapy include invasive ductal and neuroendocrine carcinoma, in addition to tubular adenocarcinoma. Although diagnosed at an age earlier compared with ciswomen, BC screening recommendations for transgenders are the same as for ciswomen. This review studies in detail the types of transgenders, their characteristics, different types of breast cancers associated, issues faced while treatment, and their best possible solutions. We also hope to have well-designed research in the future, which will fill the existing gaps in knowledge and provide scientific insight into the transgender population and issues related to their health. There are no international guidelines on screening and management of transgender patients but it appears that breast screening before cosmetic mastectomy, exposure to hormonal therapy for more than 5 years, and as per natal women screening guidelines should be offered to the patient with detailed discussion on the harms and benefits of the same.
Keywords
transgenders - breast cancer - transwomen - transmen - gender-affirming hormone therapyPublication History
Article published online:
28 July 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Abstract
The molecular pathogenesis of breast cancer (BC), the second most common cancer, varies significantly between sexes, with minimal data in the transgender population. The overall prevalence of BC in transgenders is estimated to be 0.02%. Besides experiencing social disparities, transgenders have to face a lot of discrimination in the healthcare system. Adversities faced, along with the urge to identify with physical attributes to the gender felt by them, forces transgenders to use non-prescribed hormones. Gender affirming hormone therapy (GAHT) is a key feature of transition-related care, rehabbing mental health, and the quality of life of transgenders, but at the expense of their health. Studies have reported that GAHT is associated with severe health conditions such as cancer in transgenders. Estrogens and testosterone are associated with a moderate risk of developing BC. The types of BC diagnosed in transgenders after cross-sex hormone therapy include invasive ductal and neuroendocrine carcinoma, in addition to tubular adenocarcinoma. Although diagnosed at an age earlier compared with ciswomen, BC screening recommendations for transgenders are the same as for ciswomen. This review studies in detail the types of transgenders, their characteristics, different types of breast cancers associated, issues faced while treatment, and their best possible solutions. We also hope to have well-designed research in the future, which will fill the existing gaps in knowledge and provide scientific insight into the transgender population and issues related to their health. There are no international guidelines on screening and management of transgender patients but it appears that breast screening before cosmetic mastectomy, exposure to hormonal therapy for more than 5 years, and as per natal women screening guidelines should be offered to the patient with detailed discussion on the harms and benefits of the same.
Keywords
transgenders - breast cancer - transwomen - transmen - gender-affirming hormone therapyIntroduction
Transgenders are the ones who have a gender individuality that is different from the sex at the time of birth.[1] It is estimated that from 8 to 25 million individuals worldwide now identify as transgenders.[2] The census of 2011 in India revealed the total population of transgenders to be around 4.88 lakh.[3] These people experience unique disparities in terms of social, hormonal, or surgical transition and are the subject of limited focused health research.[4] [5] As a consequence, little is known regarding the medical and mental health of transgender individuals.[6] Transgender people face psychological stress due to the uncomfortable feeling of living in a discordant gender role.[4] To reduce this distress, these people opt for various measures such as cross-sex hormone therapy (CSH) or gender-affirming hormone therapy (GAHT) apart from surgical transitions, which are reported to be associated with serious conditions such as breast and prostate cancers.[7] [8]
Breast cancer (BC) is the second most common cancer overall and the most common cancer in females with a lifetime risk of 12% and 0.1% in males.[2] [9] [10] The molecular pathogenesis of BC differs between sexes.[2] The proportion of transgender affected with BC is not known accurately although one study reported the overall prevalence of BC in transgenders to be 200 per 1,00,000 patients after years of CSH treatment in a cohort study.[10] In transgenders, the first two cases were reported in 1968 in two male to female (MtF) patients.[11] Among transgenders, transwomen (male to female) are at a higher risk of BC, as reported by de Block et al in a retrospective study.[10] In this report, we try to gain more insights into types of transgenders, GAHT, the risk associated with GAHT, patient presentation, and the dilemmas faced by this population in our society. We would also discuss the paucity of standard international guidelines on the screening and management of transgender individuals and possible solutions. Relevant clinical articles (published in the English language) included in this narrative review are selected from PubMed, Google Scholar, and appropriate websites (keywords: transgender, breast cancer, transwomen, transmen, female to male, male to female, hormone therapy). Also, transgender is a heterogeneous entity and consists of transmen and transwomen with different clinical characteristics and hormonal profiles. Below is a brief description of the types of transgenders and [Table 1] shows the differences between them.
Male to Female (MtF) |
Female to Male (FtM) |
---|---|
|
|
Transwoman |
Transman |
Assigned male sex at birth |
Assigned female sex at birth |
They require predominant hormone manipulation with estrogen and progesterone |
They require predominant hormone manipulation with testosterone |
To develop female characteristics, they usually undergo orchiectomy, vaginoplasty, breast augmentation |
Surgical intervention required is hysterectomy, oophorectomy, and phalloplasty, and subcutaneous mastectomy |
Estrogens given exogenous increase the risk of prolactinoma and breast cancer |
Exogenous testosterone increases the risk of breast and endometrial cancer |
References
- Kiran T, Davie S, Singh D. et al. Cancer screening rates among transgender adults: Cross-sectional analysis of primary care data. Can Fam Physician 2019; 65 (01) e30-e37
- Sonnenblick EB, Shah AD, Goldstein Z, Reisman T. Breast imaging of transgender individuals: a review. Curr Radiol Rep 2018; 6 (01) 1
- Sawant S.N. Transgender: status in India. Annals of Indian Psychiatry [serial online] 2017; [cited 2022 Jun 9] 1: 59-61 Available from: https://www.anip.co.in/text.asp?2017/1/2/59/220257
- Feldman J, Brown GR, Deutsch MB. et al. Priorities for transgender medical and healthcare research. Curr Opin Endocrinol Diabetes Obes 2016; 23 (02) 180-187
- Iwamoto SJ, Defreyne J, Rothman MS. et al. Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 2019; 10: 2042018819871166
- Eismann J, Heng YJ, Fleischmann-Rose K. et al. Interdisciplinary management of transgender individuals at risk for breast cancer: case reports and review of the literature. Clin Breast Cancer 2019; 19 (01) e12-e19
- Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol 2017; 5 (04) 291-300
- de Blok CJM, Klaver M, Wiepjes CM. et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab 2018; 103 (02) 532-538
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- de Blok CJM, Wiepjes CM, Nota NM. et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019; 365: l1652
- Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. part 1: male to female. Eur J Surg Oncol 2018; 44 (10) 1455-1462
- Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol 2015; 125 (03) 605-610
- Grynberg M, Fanchin R, Dubost G. et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010; 20 (04) 553-558
- ;Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93 (01) 19-25
- Phillips J, Fein-Zachary VJ, Mehta TS, Littlehale N, Venkataraman S, Slanetz PJ. Breast imaging in the transgender patient. AJR Am J Roentgenol 2014; 202 (05) 1149-1156
- Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of transgender-related discrimination and implications for health: results from the Virginia Transgender Health Initiative Study. Am J Public Health 2013; 103 (10) 1820-1829
- Rotondi NK, Bauer GR, Scanlon K, Kaay M, Travers R, Travers A. Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. Am J Public Health 2013; 103 (10) 1830-1836
- Tollinche LE, Walters CB, Radix A. et al. The Perioperative Care of the Transgender Patient. Anesth Analg 2018; 127 (02) 359-366
- Libman H, Safer JD, Siegel JR, Reynolds EE. Caring for the transgender patient: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 2020; 172 (03) 202-209
- Klein DA, Paradise SL, Goodwin ET. Caring for transgender and gender-diverse persons: what clinicians should know. Am Fam Physician 2018; 98 (11) 645-653
- Shumer DE, Nokoff NJ, Spack NP. Advances in the care of transgender children and adolescents. Adv Pediatr 2016; 63 (01) 79-102
- Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH. et al. ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 2017; Dec 23 (12) 1437
- Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer 2011; 11 (06) 417-419
- Sanchez NF, Sanchez JP, Danoff A. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health 2009; 99 (04) 713-719
- ;Randolph Jr JF. Gender-affirming hormone therapy for transgender females. Clin Obstet Gynecol 2018; 61 (04) 705-721
- Transgender Care UCSF. Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. In: Deutsch MB. ed. 2nd ed. 2016. . Available at transcare.ucsf.edu/guidelines
- Dekker MJ, Wierckx K, Van Caenegem E. et al. A European network for the investigation of gender incongruence: endocrine part. J Sex Med 2016; 13 (06) 994-999
- ;Rossouw JE, Anderson GL, Prentice RL. et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (03) 321-333
- ;Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. [abstract]. Lancet 2003; 362 (9382): 419-427
- ;Colditz GA, Hankinson SE, Hunter DJ. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. [abstract] N Engl J Med 1995; 332 (24) 1589-1593
- ;McFarlane T, Zajac JD, Cheung AS. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-a systematic review. Clin Endocrinol (Oxf) 2018; 89 (06) 700-711
- ;Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M. Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev 2017; 39 (01) 93-107
- ;Tongson K, Konovalova V, Dhawan N, Sharma S, Bahl J, Masri M. Breast cancer suspicion in a transgender male-to-female patient on hormone replacement therapy presenting with right breast mass: breast cancer risk assessment and presentation of a rare lesion. Case Rep Oncol Med 2017; 2017: 5172072 DOI: 10.1155/2017/5172072.
- ;Connelly PJ, Marie Freel E, Perry C. et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension 2019; 74 (06) 1266-1274
- ;Barghouthi N, Turner J, Perini J. Breast cancer development in a transgender male receiving testosterone therapy. Case Rep Endocrinol 2018; 2018: 3652602 DOI: 10.1155/2018/3652602.
- ;Fledderus AC, Gout HA, Ogilvie AC, van Loenen DKG. Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening. Breast 2020; 53: 92-100
- ;Mattingly AE, Kiluk JV, Lee MC. Clinical considerations of risk, incidence, and outcomes of breast cancer in sexual minorities. Cancer Contr 2016; 23 (04) 373-382
- ;Joint R, Chen ZE, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. BJOG 2018; 125 (12) 1505-1512
- ;Teoh ZH, Archampong D, Gate T. Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?. BMJ Case Rep 2015; 2015: bcr2015209396 DOI: 10.1136/bcr-2015-209396.
- ;Evans A, Trimboli RM, Athanasiou A. et al; European Society of Breast Imaging (EUSOBI), with language review by Europa Donna–The European Breast Cancer Coalition. Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging 2018; 9 (04) 449-461
- ;Smith RA, Andrews KS, Brooks D. et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68 (04) 297-316
Address for correspondence
Publication History
Article published online:
28 July 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
References
- Kiran T, Davie S, Singh D. et al. Cancer screening rates among transgender adults: Cross-sectional analysis of primary care data. Can Fam Physician 2019; 65 (01) e30-e37
- Sonnenblick EB, Shah AD, Goldstein Z, Reisman T. Breast imaging of transgender individuals: a review. Curr Radiol Rep 2018; 6 (01) 1
- Sawant S.N. Transgender: status in India. Annals of Indian Psychiatry [serial online] 2017; [cited 2022 Jun 9] 1: 59-61 Available from: https://www.anip.co.in/text.asp?2017/1/2/59/220257
- Feldman J, Brown GR, Deutsch MB. et al. Priorities for transgender medical and healthcare research. Curr Opin Endocrinol Diabetes Obes 2016; 23 (02) 180-187
- Iwamoto SJ, Defreyne J, Rothman MS. et al. Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 2019; 10: 2042018819871166
- Eismann J, Heng YJ, Fleischmann-Rose K. et al. Interdisciplinary management of transgender individuals at risk for breast cancer: case reports and review of the literature. Clin Breast Cancer 2019; 19 (01) e12-e19
- Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol 2017; 5 (04) 291-300
- de Blok CJM, Klaver M, Wiepjes CM. et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab 2018; 103 (02) 532-538
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- de Blok CJM, Wiepjes CM, Nota NM. et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019; 365: l1652
- Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. part 1: male to female. Eur J Surg Oncol 2018; 44 (10) 1455-1462
- Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol 2015; 125 (03) 605-610
- Grynberg M, Fanchin R, Dubost G. et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010; 20 (04) 553-558
- ;Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93 (01) 19-25
- Phillips J, Fein-Zachary VJ, Mehta TS, Littlehale N, Venkataraman S, Slanetz PJ. Breast imaging in the transgender patient. AJR Am J Roentgenol 2014; 202 (05) 1149-1156
- Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of transgender-related discrimination and implications for health: results from the Virginia Transgender Health Initiative Study. Am J Public Health 2013; 103 (10) 1820-1829
- Rotondi NK, Bauer GR, Scanlon K, Kaay M, Travers R, Travers A. Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. Am J Public Health 2013; 103 (10) 1830-1836
- Tollinche LE, Walters CB, Radix A. et al. The Perioperative Care of the Transgender Patient. Anesth Analg 2018; 127 (02) 359-366
- Libman H, Safer JD, Siegel JR, Reynolds EE. Caring for the transgender patient: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 2020; 172 (03) 202-209
- Klein DA, Paradise SL, Goodwin ET. Caring for transgender and gender-diverse persons: what clinicians should know. Am Fam Physician 2018; 98 (11) 645-653
- Shumer DE, Nokoff NJ, Spack NP. Advances in the care of transgender children and adolescents. Adv Pediatr 2016; 63 (01) 79-102
- Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH. et al. ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 2017; Dec 23 (12) 1437
- Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. Clin Breast Cancer 2011; 11 (06) 417-419
- Sanchez NF, Sanchez JP, Danoff A. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health 2009; 99 (04) 713-719
- ;Randolph Jr JF. Gender-affirming hormone therapy for transgender females. Clin Obstet Gynecol 2018; 61 (04) 705-721
- Transgender Care UCSF. Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. In: Deutsch MB. ed. 2nd ed. 2016. . Available at transcare.ucsf.edu/guidelines
- Dekker MJ, Wierckx K, Van Caenegem E. et al. A European network for the investigation of gender incongruence: endocrine part. J Sex Med 2016; 13 (06) 994-999
- ;Rossouw JE, Anderson GL, Prentice RL. et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (03) 321-333
- ;Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. [abstract]. Lancet 2003; 362 (9382): 419-427
- ;Colditz GA, Hankinson SE, Hunter DJ. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. [abstract] N Engl J Med 1995; 332 (24) 1589-1593
- ;McFarlane T, Zajac JD, Cheung AS. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-a systematic review. Clin Endocrinol (Oxf) 2018; 89 (06) 700-711
- ;Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M. Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev 2017; 39 (01) 93-107
- ;Tongson K, Konovalova V, Dhawan N, Sharma S, Bahl J, Masri M. Breast cancer suspicion in a transgender male-to-female patient on hormone replacement therapy presenting with right breast mass: breast cancer risk assessment and presentation of a rare lesion. Case Rep Oncol Med 2017; 2017: 5172072 DOI: 10.1155/2017/5172072.
- ;Connelly PJ, Marie Freel E, Perry C. et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension 2019; 74 (06) 1266-1274
- ;Barghouthi N, Turner J, Perini J. Breast cancer development in a transgender male receiving testosterone therapy. Case Rep Endocrinol 2018; 2018: 3652602 DOI: 10.1155/2018/3652602.
- ;Fledderus AC, Gout HA, Ogilvie AC, van Loenen DKG. Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening. Breast 2020; 53: 92-100
- ;Mattingly AE, Kiluk JV, Lee MC. Clinical considerations of risk, incidence, and outcomes of breast cancer in sexual minorities. Cancer Contr 2016; 23 (04) 373-382
- ;Joint R, Chen ZE, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. BJOG 2018; 125 (12) 1505-1512
- ;Teoh ZH, Archampong D, Gate T. Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?. BMJ Case Rep 2015; 2015: bcr2015209396 DOI: 10.1136/bcr-2015-209396.
- ;Evans A, Trimboli RM, Athanasiou A. et al; European Society of Breast Imaging (EUSOBI), with language review by Europa Donna–The European Breast Cancer Coalition. Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging 2018; 9 (04) 449-461
- ;Smith RA, Andrews KS, Brooks D. et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68 (04) 297-316